Daniel Alkon
President chez NEUROTROPE, INC.
Fortune : 6 683 $ au 31/03/2024
Profil
Daniel L.
Alkon is currently the President, Director & Chief Scientific Officer at Synaptogenix, Inc. and the President & Chief Scientific Officer at Neurotrope, Inc. He previously worked as the Scientific Director & Professor at Blanchette Rockefeller Neurosciences Institute from 1999 to 2016.
He also served as the Medical Director at the National Institute of Neurological Disorders & Stroke.
Additionally, he worked as a Principal at Adaptive Systems, Inc. and as a Professor-Neurology at West Virginia University.
Dr. Alkon received his undergraduate degree from the University of Pennsylvania in 1965 and his doctorate from Cornell University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SYNAPTOGENIX, INC.
0,17% | 25/03/2024 | 35 547 ( 0,17% ) | 6 683 $ | 31/03/2024 |
Postes actifs de Daniel Alkon
| Sociétés | Poste | Début |
|---|---|---|
| NEUROTROPE, INC. | President | 19/09/2016 |
| SYNAPTOGENIX, INC. | President | - |
Anciens postes connus de Daniel Alkon
| Sociétés | Poste | Fin |
|---|---|---|
Blanchette Rockefeller Neurosciences Institute
 Blanchette Rockefeller Neurosciences Institute BiotechnologyHealth Technology Blanchette Rockefeller Neurosciences Institute provides health care solutions. The company offers to facilitate molecular signaling, which controls the functions that record our conscience experience. The company is headquartered in Morgantown, WV. | Chief Tech/Sci/R&D Officer | 23/09/2016 |
| West Virginia University | Corporate Officer/Principal | 01/09/2016 |
Adaptive Systems, Inc.
 Adaptive Systems, Inc. Computer Processing HardwareElectronic Technology Adaptive Systems, Inc. manufactures and develops small, high performance modular hardware products for use by the embedded computer industry. It products include 486DX 66MHz, 586-133MHz Processors; System Management; Super I/O, VGA, PCMCIA; and Sound O/S. The company is headquartered in Longmont, CO. | Corporate Officer/Principal | - |
| National Institute of Neurological Disorders & Stroke | Chief Tech/Sci/R&D Officer | - |
Formation de Daniel Alkon
| University of Pennsylvania | Undergraduate Degree |
| Cornell University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Neurotrope, Inc.
 Neurotrope, Inc. Pharmaceuticals: MajorHealth Technology Neurotrope, Inc. is a biopharmaceutical company, which engages in the pre-clinical and clinical development of its product candidates. The company focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C. The company was founded on January 11, 2011 and is headquartered in New York, NY. | Health Technology |
Adaptive Systems, Inc.
Adaptive Systems, Inc. Computer Processing HardwareElectronic Technology Adaptive Systems, Inc. manufactures and develops small, high performance modular hardware products for use by the embedded computer industry. It products include 486DX 66MHz, 586-133MHz Processors; System Management; Super I/O, VGA, PCMCIA; and Sound O/S. The company is headquartered in Longmont, CO. | Electronic Technology |
Blanchette Rockefeller Neurosciences Institute
Blanchette Rockefeller Neurosciences Institute BiotechnologyHealth Technology Blanchette Rockefeller Neurosciences Institute provides health care solutions. The company offers to facilitate molecular signaling, which controls the functions that record our conscience experience. The company is headquartered in Morgantown, WV. | Health Technology |
| National Institute of Neurological Disorders & Stroke | Government |
| Synaptogenix, Inc. |
